Wishing you al a very happy Thanksgiving. I am very thankful this year for MDXG. I imagine Candy/Cezz and the chubby reporter are not thankful they ever heard of the symbol MDXG. Don't overeat chubby reporter!
Candy, this is yet another "great opportunity" to average up your basis on your short!
earth. I pasted that from the nasdaq website. if you enter MDXG then hit short interest tab on left side you will find the link to the schedule when it hits the website.
Publication Schedule for 2014
Settlement Date Due Date- 6 p.m. Dissemination Date
after 4 p.m., ET
January 1/15/2014 1/17/2014 1/27/2014
1/31/2014 2/04/2014 2/11/2014
February 2/14/2014 2/19/2014 2/26/2014
2/28/2014 3/04/2014 3/11/2014
March 3/14/2014 3/18/2014 3/25/2014
3/31/2014 4/02/2014 4/09/2014
April 4/15/2014 4/17/2014 4/25/2014
4/30/2014 5/02/2014 5/09/2014
May 5/15/2014 5/17/2014 5/27/2014
5/30/2014 6/03/2014 6/10/2014
June 6/13/2014 6/17/2014 6/24/2014
6/30/2014 7/02/2014 7/10/2014
July 7/15/2014 7/17/2014 7/24/2014
7/31/2014 8/04/2014 8/11/2014
August 8/15/2014 8/19/2014 8/26/2014
8/29/2014 9/03/2014 9/10/2014
September 9/15/2014 9/17/2014 9/24/2014
9/30/2014 10/02/2014 10/09/2014
October 10/15/2014 10/17/2014 10/24/2014
10/31/2014 11/04/2014 11/11/2014
November 11/14/2014 11/18/2014 11/25/2014
11/28/2014 12/02/2014 12/09/2014
December 12/15/2014 12/17/2014 12/24/2014
12/31/2014 1/05/2015 1/12/2015
umm, how bout, do you realize that institutions do over 1/2 their volume in 90 minutes during the day the biggest period being 3:30-4;00? There will be plenty of window dressing this time of year locking in gains and tax losses as well for losers. Nothing to do with shorts
Company said they still expect a 5 cent dividend for Q1 and once everything is leased out, which they expect to happen by the end of Q1 (although regulatory approval will come after that) cash flow would support a 40 cent/year dividend. That yield should make the stock worth $7 plus IMO. Question here is execution and the new CEO has a track record to get this done. Given the company's assets, I see this as a low risk high reward play at this price
Nekkoddd, pump you garbage elsewhere. Wouldn't touch anything Jason touts. His specialty is sub $1 stocks that never amount to anything.
Agreed. For calendar 2015, ALQA is expected to be 1/20 the size of MDXG. I cannot opine on ALQA's products but MDXG will be gone while ALQA is still in the stock selling business
It could be 2016 before a sale.....all depends on how long Petit wants to stick it out and grow the business. Options are sell now at maybe 16 or wait a year until the stock is closeer to 20 and sell mid 20s or higher. Nice to be in a position to be faced with decisions like that.
Seeking Alpha doesn't write articles. People like you and I write articles and submit them to SA and SA posts them. I have chatted with this author in days gone by. He has a basic understanding of what MDXG does but not an "in depth" understanding, in my opinion.
babykahn, yes, it is amazing how all the doctors and hospitals have been "fooled" by studies from MDXG that do not hold true when they actually use MDXG product on their patients. I mean, the doctors and hospitals including the VA continue to order MDXG product even after they treat their patients. Don't they see that MDXG's studies are bogus and the product doesn't really do what MDXG claims it does? Are the thousands of docs that have used the product all incompetent or what? LOL! You are dumb beyond words.
Bind drops on mixed Phase 2 lung cancer data • 10:51 AM
Douglas W. House, SA News Ed...
•Thinly-traded nano cap Bind Therapeutics (BIND -15.5%) slumps on a 2x surge in volume albeit on turnover of only 170K shares.
•This morning, the company reported results from its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC). The study met its primary efficacy endpoint of overall response rate (ORR) in the once/three weeks (Q3W) arm (40 patients). Five patients (12.5%) achieved a partial response with a median duration of response of 5.2 months and median progression-free survival (PFS) of 2.7 months. Two of nine KRAS mutation-positive patients experienced an objective response (22.2%; 2/9) with median PFS of 2.7 months.
•There were no confirmed objective responses in patients with squamous cell carcinoma (SCC). Median PFS was 2.8 months.
•Preliminary median overall survival (OS) was 6.2 months for all patients treated, 9.6 months in KRAS-positive patients and 11.1 months in patients with SCC.
•In light of the results from the Q3W arm, enrollment in the weekly arm will be terminated.
•The company plans to initiate global multicenter Phase 2 studies of BIND-014 in NSCLC patients with the KRAS mutation and in NSCLC patients of squamous histology who have progressed on prior therapy.